newsfilter
← Latest News
GlobeNewswire·

Finch Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

New positive topline data from 132-participant PRISM-EXT Phase 2 open-label trial of CP101 in recurrent C. difficile infection (CDI) show 80.3% sustained clinical cure rate through 8 weeks, with a similar rate maintained through 24 weeks New data pres